Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of Hydronidone in Chronic Hepatitis B with Liver Fibrosis
NCT04123769Phase 1Completed
- Sponsor
- Gyre Pharmaceuticals
- Start
- Sep 2019
- Primary completion
- Oct 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of hydronidone in Liver Fibrosis (LF), sponsored by Gyre Pharmaceuticals. Primary endpoints: Maximum Plasma Concentration up to 24 weeks, Time to Maximum Plasma Concentration up to 24 weeks and 2 more. Started Sep 2019; status: completed.
02
Drugs
hydronidone
03
Conditions
Liver Fibrosis (LF)
Beyond the preview
Go deeper on NCT04123769.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04123769.